{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T10:04:58Z","timestamp":1762250698272,"version":"build-2065373602"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Veterinary Immunology and Immunopathology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.vetimm.2025.110925","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T13:16:29Z","timestamp":1743254189000},"page":"110925","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Establishment of B4-100 and B4-C4, clonal canine multiple myeloma cell lines and their application in generating monoclonal antibody-producing fully canine hybridomas"],"prefix":"10.1016","volume":"283","author":[{"given":"Mark J.","family":"Micallef","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaori","family":"Torihama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Fujikake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Kumagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunori","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gakuto","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoji","family":"Ogino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiro","family":"Tsukui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.vetimm.2025.110925_bib1","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1182\/bloodadvances.2021005045","article-title":"Bite-size introduction to canine hematologic malignancies","volume":"6","author":"Atheron","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.vetimm.2025.110925_bib2","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1021\/acs.chemrestox.9b00215","article-title":"Cell Lines as biological models: practical steps for more reliable research","volume":"32","author":"Capes-Davis","year":"2019","journal-title":"Chem. Res. Toxicol."},{"issue":"21","key":"10.1016\/j.vetimm.2025.110925_bib3","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1200\/JCO.2010.27.9836","article-title":"Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies","volume":"28","author":"Cheson","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.vetimm.2025.110925_bib4","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0145-2126(99)00195-2","article-title":"Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia","volume":"24","author":"Drexler","year":"2000","journal-title":"Leuk. Res."},{"issue":"2","key":"10.1016\/j.vetimm.2025.110925_bib5","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1182\/blood.V73.2.566.566","article-title":"Phenotypic analysis of human myeloma cell lines","volume":"74","author":"Duperray","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.vetimm.2025.110925_bib6","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/nri802","article-title":"Development of anti-TNF therapy for rheumatoid arthritis","volume":"2","author":"Feldman","year":"2002","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.vetimm.2025.110925_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.941437","article-title":"Molecular impact of the tumor microenvironment on multiple myeloma dissemination and extramedullary disease","volume":"12","author":"Forster","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.vetimm.2025.110925_bib8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0076-6879(81)73054-4","article-title":"Preparations of monoclonal antibodies: strategies and procedures","volume":"73","author":"Gafre","year":"1981","journal-title":"Methods Enzym."},{"key":"10.1016\/j.vetimm.2025.110925_bib9","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/jvim.13985","article-title":"In vitro and in vivo characterization of a fully felinized therapeutic anti-nerve growth factor monoclonal antibody for the treatment of pain in cats","volume":"30","author":"Gearing","year":"2016","journal-title":"J. Vet. Intern. Med."},{"key":"10.1016\/j.vetimm.2025.110925_bib10","first-page":"429","article-title":"Canine IgE monoclonal antibody specific for a filarial antigen: production by a canine x murine heterohybridoma using B cells from a clinically affected lymph node","volume":"85","author":"Gebhard","year":"1995","journal-title":"Immunology"},{"issue":"9","key":"10.1016\/j.vetimm.2025.110925_bib11","doi-asserted-by":"crossref","DOI":"10.1101\/pdb.prot103325","article-title":"Selecting for and checking cells with HGPRT deficiency for hybridoma production","volume":"2021","author":"Greenfield","year":"2021","journal-title":"Cold Spring Harb. Protoc."},{"issue":"4","key":"10.1016\/j.vetimm.2025.110925_bib12","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0301-472X(03)00023-7","article-title":"Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and \u2013resistant MM cells","volume":"31","author":"Greenstein","year":"2003","journal-title":"Exp. Hematol."},{"issue":"3","key":"10.1016\/j.vetimm.2025.110925_bib13","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4161\/mabs.2.3.11641","article-title":"The immunogenicity of humanized and fully human antibodies","volume":"2","author":"Harding","year":"2010","journal-title":"MAbs"},{"issue":"7","key":"10.1016\/j.vetimm.2025.110925_bib14","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1128\/JCM.02286-09","article-title":"Establishment and characterization of a Madin-Darby canine kidney reporter cell line for influenza A virus assays","volume":"48","author":"Hossain","year":"2010","journal-title":"J. Clin. Microbiol."},{"issue":"3","key":"10.1016\/j.vetimm.2025.110925_bib15","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1365-2249.1991.tb05653.x","article-title":"Human hybridomas derived from CD5+ B lymphocytes of patients with chronic lymphocytic leukaemia (B-cll) produce multi-specific natural IgM (kappa) antibodies","volume":"83","author":"Jahn","year":"1991","journal-title":"Clin. Exp. Immunol."},{"issue":"4","key":"10.1016\/j.vetimm.2025.110925_bib16","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1073\/pnas.98.4.1799","article-title":"A human myeloma cell line suitable for the generation of human monoclonal antibodies","volume":"98","author":"Karpas","year":"2001","journal-title":"PNAS"},{"key":"10.1016\/j.vetimm.2025.110925_bib17","first-page":"1178","article-title":"Establishment and characterization of canine thyroid adenocarcinoma and canine melanoma cell lines","volume":"25","author":"Kasza","year":"1964","journal-title":"Am. J. Vet. Res."},{"issue":"3","key":"10.1016\/j.vetimm.2025.110925_bib18","doi-asserted-by":"crossref","first-page":"939","DOI":"10.4049\/jimmunol.1102107","article-title":"Natural IgM in immune equilibrium and harnessing their therapeutic potential","volume":"188","author":"Kaveri","year":"2012","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.vetimm.2025.110925_bib19","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/eji.1830060713","article-title":"Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion","volume":"6","author":"Kohler","year":"1976","journal-title":"Eur. J. Immunol."},{"issue":"4","key":"10.1016\/j.vetimm.2025.110925_bib20","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/iid3.531","article-title":"Development and characterization of a unique anti-IgE mouse monoclonal antibody cross-reactive between human and canine IgE","volume":"9","author":"Kumagai","year":"2021","journal-title":"Immun. Inflamm. Dis."},{"key":"10.1016\/j.vetimm.2025.110925_bib21","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.21873\/anticanres.13741","article-title":"Antitumor activity of rivoceranib against canine mammary gland tumor cell lines","volume":"39","author":"Lee","year":"2019","journal-title":"Anticancer Res."},{"key":"10.1016\/j.vetimm.2025.110925_bib22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3324\/haematol.2008.001628","article-title":"Anti-CD20 monoclonal antibodies: historical and future perspectives","volume":"95","author":"Lim","year":"2010","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.vetimm.2025.110925_bib23","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3390\/cancers11081098","article-title":"Cancer cell lines are useful model systems for medical research","volume":"11","author":"Mirabelli","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.vetimm.2025.110925_bib24","series-title":"Multiple Myeloma \u2013 A Quick Reflection on the Fast Progress","first-page":"289","article-title":"Multiple myeloma in horses, dogs and cats: a comparative review focused on clinical signs and pathogenesis","author":"Munoz","year":"2013"},{"issue":"2-4","key":"10.1016\/j.vetimm.2025.110925_bib25","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.vetimm.2010.09.002","article-title":"Establishment of a quantitative ELISA for the measurement of allergen-specific IgE in dogs using anti-IgE antibody cross-reactive to mouse and dog IgE","volume":"139","author":"Okayama","year":"2011","journal-title":"Vet. Immunol. Immunopathol."},{"issue":"4","key":"10.1016\/j.vetimm.2025.110925_bib26","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1939-165X.2005.tb00059.x","article-title":"Multiple myeloma in 16 cats: a retrospective study","volume":"34","author":"Patel","year":"2005","journal-title":"Vet. Clin. Pathol."},{"issue":"1","key":"10.1016\/j.vetimm.2025.110925_bib27","doi-asserted-by":"crossref","first-page":"21","DOI":"10.32932\/rpia.2022.03.075","article-title":"Efficacy and safety of lokivetmab (Cytopoint) for the control of pruritus and skin lesions in dogs with atopic dermatitis","volume":"30","author":"Pinto","year":"2022","journal-title":"Rev. Port. Imunoalergologia"},{"key":"10.1016\/j.vetimm.2025.110925_bib28","first-page":"849","article-title":"Multiple myeloma and primary erythrocytosis in a dog","volume":"62","author":"Ricci","year":"2021","journal-title":"Can. Vet. J."},{"key":"10.1016\/j.vetimm.2025.110925_bib29","doi-asserted-by":"crossref","first-page":"6443","DOI":"10.21873\/anticanres.13858","article-title":"Establishment of drug-resistant cell lines as a model in experimental oncology","volume":"39","author":"Sales Amaral","year":"2019","journal-title":"Anticancer Res."},{"key":"10.1016\/j.vetimm.2025.110925_bib30","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nrc1951","article-title":"The NCI60 human tumour cell line anticancer drug screen","volume":"6","author":"Shoemaker","year":"2006","journal-title":"Nat. Rev. Cancer"},{"issue":"5223","key":"10.1016\/j.vetimm.2025.110925_bib31","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1126\/science.7542801","article-title":"A role for CD5 in TCR-mediated signal transduction and thymocyte selection","volume":"269","author":"Tarakhovsky","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.vetimm.2025.110925_bib32","first-page":"271","article-title":"Cancer drug resistance in multiple myeloma","volume":"5","author":"Uckun","year":"2022","journal-title":"Cancer Drug Resist."}],"container-title":["Veterinary Immunology and Immunopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165242725000455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165242725000455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T10:00:34Z","timestamp":1762250434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165242725000455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":32,"alternative-id":["S0165242725000455"],"URL":"https:\/\/doi.org\/10.1016\/j.vetimm.2025.110925","relation":{},"ISSN":["0165-2427"],"issn-type":[{"type":"print","value":"0165-2427"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Establishment of B4-100 and B4-C4, clonal canine multiple myeloma cell lines and their application in generating monoclonal antibody-producing fully canine hybridomas","name":"articletitle","label":"Article Title"},{"value":"Veterinary Immunology and Immunopathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vetimm.2025.110925","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110925"}}